Inpeco and Bio-Rad Partner to Connect Total Lab Automation Solution and Smart HPLC Technology

Print

Date: 10/08/2018

Press Release

Inpeco and Bio-Rad Partner to Connect Total Lab Automation Solution and Smart HPLC Technology

NOVAZZANO, CH and HERCULES, Calif. — October 10, 2018 — Inpeco S.A., the privately held leader in total laboratory automation (TLA) solutions and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced their partnership to connect the Inpeco FlexLab track for clinical laboratory automation and the D-100 System, to provide high-volume laboratories improved operational efficiencies to meet the growing worldwide demand for diabetes testing.

Inpeco designs, develops, and manufactures customized TLA solutions that are modular, open, scalable, and fast. Their solutions offer labs automation and traceability, from collection to results improving their diagnostic workflow.

Bio-Rad brings over 40 years of expertise in diabetes testing to the D-100 System, which aids in the diagnosis and monitoring of diabetes. The D-100 features Smart HPLC, designed to meet the quality and productivity demands of high-volume labs. Bio-Rad's onboard Advisor software automatically reviews results.

"A distinctive feature of our FlexLab TLA solution is its open connectivity," said Gigi Minola, Inpeco Vice President. "An open system connection gives customers the freedom to choose the instruments they prefer to use for their complete lab automation. We are thrilled to meet our customers' needs by connecting Bio-Rad's D-100 instrument to our TLA solution."

"We are pleased to partner with Inpeco to connect the D-100 System to the Inpeco FlexLab automated track system," said John Hertia, Bio-Rad President, Clinical Diagnostics Group. "With Inpeco's solution, we can provide our customers the benefits of our D-100 instrument along with the workflow efficiencies of total laboratory automation."


About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Radnobr> had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio rad.com.


About Inpeco, S.A.
Since 1990, Inpeco S.A. has specialized in providing automation solutions to improve and simplify the process and operations of any-size laboratories, from collection to result. With 1700 solutions installed all over the world, Inpeco has gained unparalleled expertise in automation, robotics, sample and data management, and patient-related activities. Inpeco was awarded the Frost & Sullivan's 2018 Company of the Year recognition in the Clinical Lab Automation area For more information, visit www.inpeco.com.


Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "can," "plan," "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


Press contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-6063
tina_cuccia@bio-rad.com

Inpeco S.A.
Lucilla Mariani, Communications Director
lucilla.mariani@inpeco.com

Sign Up for Bio-Rad Updates!
Enter your email address below to receive your choice of the latest news, promotions, and more.
Get Help

Call us at 00 800 00 BIORAD (00 800 00 24 67 23) or +49 89 3188 4393

To give you the very best experience, the cookie settings on Bio-Rad.com are set to "allow all cookies". To change your settings please click  here.  Close